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Objective: To determine the clinical characteristics and outcomes of patients with lungdomi-
nant connective tissue disease (LD-CTD) with a usual interstitial pneumonia (UIP) who do not
meet the criteria for any form of CTD, and to compare these parameters with those of patients
with idiopathic pulmonary fibrosis (IPF/UIP) and CTD-associated-UIP.
Methods: We conducted a prospective study on 118 patients diagnosed with UIP [LD-CTD,
nZ 28; CTDUIP, nZ 29; and IPF/UIP, nZ 61]. We compared the clinical characteristics, phys-
iological findings, serum albumin concentrations, high-resolution computed tomography
(HRCT) imaging data, and outcomes among the three groups and used Cox’s proportional
hazards regression analysis to identify variables associated with an increased risk of death.
Results: The LD-CTD and CTD-UIP patients were younger, more often female, and predomi-
nantly nonsmokers, compared with the IPF/UIP group. A significant difference in survival
was evident between patients in the CTD-UIP and IPF/UIP groups (pZ 0.028), but not between
LD-CTD and IPF/UIP (p Z 0.164) or between LD-CTD and CTD-UIP (p Z 0.254). The variables
associated with poorer survival in all UIP patients were (reduced) initial SpO2 level (hazard
ratio [HR], 2.89; 95% confidence interval [CI] 2.1e3.7; p Z 0.009) and lower serum albumin
concentration (HR 2.16; 95% CI 1.6e2.7; p Z 0.008).
Conclusions: LD-CTD has distinct clinical characteristics that suggest an autoimmune back-
ground resembling that of CTD-UIP but differing from that of IPF/UIP. However, LD-CTD withhalid University Hospital, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.
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1576 E.H. Alhamad et al.a UIP pattern was not associated with improved survival. The resting oxygen saturation level
and serum albumin concentration were independent predictors of mortality in all of the
studied UIP patients, regardless of UIP type.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Usual interstitial pneumonia (UIP), a subtype of interstitial
lung disease (ILD) that is frequently encountered in
patients with connective tissue disease (CTD), has a better
prognosis than idiopathic pulmonary fibrosis (IPF).1e4
The lungs may be the primary site of initial clinical
symptoms in any of the CTDs, antedating the systemic
manifestations by months or even years. However, the
current classification system established by the American
College of Rheumatology (ACR) does not recognize ILD in
the absence of well-defined extrathoracic manifestations
as a diagnostic criterion for CTD, except as a minor crite-
rion for systemic sclerosis. As such, it can be challenging to
differentiate between idiopathic interstitial pneumonia
(IIP) and ILD that does not meet the ACR criteria for any of
the CTDs. Recently, the international guidelines for the
diagnosis and management of IPF were revised to recom-
mend serological testing, including assays for antinuclear
antibody (ANA), rheumatoid factor (RF), and anti-cyclic
citrullinated peptide (anti-CCP), in the absence of signs or
symptoms of CTD.5 However, screening IPF patients for only
these autoantibodies risks missing a subset of patients with
subclinical CTD that has been misclassified as IIP.6
Furthermore, it is not uncommon to see mildly positive
ANA titers in IPF patients.5 However, consideration of ANA
positivity along with nucleolar staining patterns may allow
us to identify patients that fit the diagnostic criteria for
systemic sclerosis sine scleroderma among patient origi-
nally diagnosed as IPF.7
The term ‘undifferentiated CTD (UCTD)’ has been
proposed to describe patients who have symptoms and signs
suggestive of autoimmune disease, do not fulfill the clas-
sification criteria for any of the defined CTDs, have
a disease duration of more than 1 year, and have positive
serological results.8,9 Studies have suggested that the
majority of UCTD cases will remain undifferentiated, with
a mild clinical course and favorable prognosis.10,11
However, little is known about patients who show UIP
patterns and lack the symptoms or signs suggestive of
autoimmune disease. Recently, Fischer et al.12 proposed
provisional criteria for the diagnosis of lung-dominant (LD)-
CTD, recognizing that the presence of specific autoanti-
bodies and histopathological features, even in the absence
of extrathoracic features of a definite CTD, is sufficient to
characterize a patient as having CTD-associated interstitial
pneumonia.
Here, we investigated differences in the clinical char-
acteristics, radiographic findings and prognoses among
patients diagnosed with LD-CTD with a UIP pattern
compared to those diagnosed with idiopathic pulmonary
fibrosis (IPF/UIP) and CTD associated-UIP. We hypothesized
that applying the proposed diagnostic criteria for LD-CTDwould yield a distinct phenotype that might be associated
with a particular autoimmune background.
Methods
Study population
This is a prospective clinical descriptive study of consecu-
tive patients diagnosed with UIP based on high-resolution
computed tomography (HRCT) and/or surgical lung biopsy
between January 2008 and December 2010. The study was
approved by the Institutional Review Board/Ethics
Committee of the College of Medicine, King Saud Univer-
sity, Riyadh, Saudi Arabia. Written informed consent was
obtained from all study participants.
Serological tests, including those for ANA, RF, anti-CCP,
anti-Ro/SSA, anti-La/SSB, anti-double-stranded DNA
(dsDNA), anti-Smith, anti-Sclero 70 (Scl-70), anti- ribonu-
cleoprotein (RNP), anti-histidyl-tRNA synthetase (Jo-1), and
anti-centromere antibodies (ACA), were performed
routinely when ILD was first suspected. CTD was diagnosed
when patients fulfilled the ACR criteria for rheumatoid
arthritis, systemic lupus erythematosus, systemic sclerosis,
polymyositis/dermatomyositis, Sjogren’s syndrome, or
mixed CTD.13e18 LD-CTD was diagnosed based on the criteria
proposed by Fischer et al.12 (Table 1). LD-CTD patients were
also asked (during their ILD clinic visits and by telephone
every three months) about the presence of Raynaud’s
phenomenon, arthralgia/multiple joint swelling, photosen-
sitivity, unintentional weight loss, morning stiffness, dry
mouth, dry eyes, dysphagia, skin rash, oral ulceration, and
proximal muscle weakness. All CTD-UIP (n Z 29) and
a majority of the LD-CTD (n Z 21) patients were seen and
followed regularly by rheumatologists. IPF/UIP was diag-
nosed according to the American Thoracic Society/European
Respiratory Society consensus classification.19
One hundred-thirty-six patients with other causes of ILD
seen during the study period were excluded; these
included cases of sarcoidosis (n Z 53); nonspecific inter-
stitial pneumonia (n Z 49); hypersensitivity pneumonitis
(n Z 12); smoking-related ILD (n Z 9); unclassifiable
fibrosis (n Z 6); organizing pneumonia (n Z 4); and
lymphocytic interstitial pneumonia (n Z 3). In addition, 10
patients were excluded because HRCT was not available
and serological tests were not performed. The follow-up
period for our analysis of survival data ended in May, 2011.
Measurements
Pulmonary function tests (PFT Masterscreen; Jaeger, Hoech-
berg, Germany) were performed using standard methodolo-
gies; these included spirometry, plethysmography, and
Table 1 Diagnostic criteria for LD-CTD.
1. UIP pattern determined from surgical lung biopsy or
suggested by high-resolution CT and
2. Insufficient extrathoracic features to allow a specific
CTD designation and
3. No identifiable alternative etiology for UIP and
4. Any one of the following autoantibodies or at least two
of the following histopathological features:
Autoantibodies Histopathological features
a High-titer ANA (>1:320)
or RF (>60 IU/mL)
(a) Lymphoid aggregates
with germinal centers
b Nucleolar-ANA (b) Extensive pleuritis
c Anti-CCP (c) Prominent plasmacytic
infiltration
d Anti-Scl-70 (d) Dense perivascular
collagen
e Anti-Ro/SSA
f Anti-La/SSB
g Anti-ds DNA
h Anti-Smith
i Anti-RNP
j Anti-JO-1
k ACA
Criteria derived from Reference 12.
Abbreviations: LD-CTD Z lung-dominant connective tissue
disease; UIPZ usual interstitial pneumonia; CTDZ connective
tissue disease; ANA Z antinuclear antibody; RF Z rheumatoid
factor; CCP Z cyclic citrullinated peptide; Scl-70 Z Sclero 70;
dsDNA Z double-stranded DNA; RNP Z ribonucleoprotein; JO-
1Z anti-histidyl-tRNA synthetase; and ACAZ anti-centromere
antibodies.
Autoimmune usual interstitial pneumonia 1577measurement of the diffusion capacity of the lung for carbon
monoxide (DLco).20e22 The reference values were taken from
Quanjer et al.23 Arterial blood gas values (Rapid Lab 865;
Bayer, Plymouth,UK)wereobtained for thepartial pressureof
oxygen (PaO2), the partial pressureof carbondioxide (PaCO2),
and the extent of oxygen saturation (SaO2). The 6-min walk
test (6MWT) was conducted in accordance with ATS guide-
lines.24 Heart rate, blood pressure, oxygen saturation (SpO2),
and the Borg dyspnea index25 were recorded at the beginning
and end of a 6-min walk. At the end of the test, the total
distance walked (in meters; 6MWD) was documented.
Pulmonary function tests, arterial blood gas analyses, and
6MWTs were performed when ILD was first suspected. The
serum albumin concentration was obtained within one month
of the initial evaluation at the ILD clinic.
Right heart catheterization (n Z 80) was performed
when pulmonary hypertension (PH) was suspected on clin-
ical examination, when the predicted diffusion capacity of
the lung for carbon monoxide (DLco) was <40%, or when
oxygen desaturation of <88% was evident during the 6MWT.
Data were derived using standard techniques,26 and
included measurement of pulmonary artery pressure (PAP).
PH was defined as a mean resting PAP 25 mmHg.27
Chest CT
All patients underwent CT scanning (Light Speed 16 or VCT
XT; GE Medical Systems, Milwaukee, WI, USA). Full-volumescans reconstructed every 2.5mmwere obtained throughout
the entire thorax. Scans were performed during suspended
inspiration, with patients in the supine position. Additional
limited scans using 1.25-mm thin collimation at 10-mm
intervals from the aortic arch level to the lung bases, with
high spatial resolution reconstruction, were obtained at end-
expiration with patients in the prone position.
CT evaluation
HRCT scans were evaluated by a chest radiologist experi-
enced in the interpretation of diffuse lung disease. CT
images were assessed for the presence and extent of
parenchymal abnormalities, including ground-glass opacity,
reticular opacity, honeycombing, traction bronchiectasis,
emphysema, and architectural distortion. The radiological
pattern was categorized as a typical UIP pattern if sub-
pleural, predominantly basal reticulation and honey-
combing with rare or no ground-glass opacities were
demonstrated. The pattern was categorized as a nontypical
UIP pattern if it lacked honeycombing and had more
ground-glass opacities. The extent of parenchymal abnor-
mality was determined for each complete lung using
a previously described 5-point scale28,29 (0 Z no involve-
ment; 1 Z 1e25%; 2 Z 26e50%; 3 Z 51e75%; and
4Z 76e100%). Each lung was scored separately and divided
into three zones (upper zone, lung apex to aortic arch;
middle zone, aortic arch to a position inferior to the
pulmonary veins; and lower zone, from the inferior
pulmonary veins to the diaphragm). A mean score for each
of the six zones was calculated for each parenchymal
pattern (i.e., ground-glass opacity, reticular opacity, hon-
eycombing, traction bronchiectasis, emphysema, and
architectural distortion). Total lung involvement was
determined by summing the scores for each CT pattern
(total extent).
Pathological analysis
Surgical lung biopsies were reviewed by a pathologist who
was blind to the clinical information. Histopathological
evidence of UIP was determined according to the American
Thoracic Society and European Respiratory Society
Consensus Classification criteria.19 Specimens were avail-
able for 14.7% (9 of 61) patients with IPF/UIP, for 3.4% (1 of
29) patients with CTD-UIP, and for 14.3% (4 of 28) patients
with LD-CTD. Specific histopathological features were
examined for the presence of dense perivascular collagen,
lymphoid aggregates with germinal center formation,
extensive pleuritis, and prominent plasmacytic infiltration.
Statistical analysis
Descriptive statistics (means, standard deviations and
percentages) were used to describe the quantitative and
categorical study variables. One-way analysis of variance
was used to compare the means of all quantitative variables
in relation to the LD-CTD, CTD-UIP and IPF/UIP groups.
Pearson’s chi-square statistics or Fisher’s exact test
were used for categorical variables. For survival, the
KaplaneMeier method was used to investigate the time
1578 E.H. Alhamad et al.from the first respiratory symptom until the last follow-up
in the ILD clinic or death (i.e., disease duration). The data
of patients who had been lost to follow-up were considered
censored observations. Cox’s proportional hazard regres-
sion analysis was used to obtain unadjusted hazard ratios
for all the study variables in relation to mortality for LD-
CTD, CTD-UIP, and IPF/UIP. Adjusted hazard ratios were
obtained to identify the independent predictors of
mortality for IPF/UIP patients and in all studied UIP
patients, regardless of UIP type. A two-sided p-value
of < 0.05 and 95% confidence intervals were used to report
the statistical significance and the precision of our results,
respectively. The SPSS version 16 software package (SPSS
Inc., Chicago, IL, USA) was used for all analyses.Results
Demographic and clinical characteristics
One-hundred-and-eighteen patients with UIP comprised the
study cohort. Twenty-eight patients met the criteria for LD-
CTD, 29 for CTD-UIP, and 61 for IPF/UIP.
The CTD-UIP patients had associated diagnoses of
rheumatoid arthritis (nZ 12), mixed CTD (nZ 6), systemic
lupus erythematosus (n Z 5), scleroderma (n Z 4), andTable 2 Demographic and clinical characteristics of the study
Characteristics LD-CTD n Z 28
Age at presentation, years 56.6  13.7
Female gender, n (%) 19 (67.9)
Ever smoker, n (%) 3 (10.7)
Disease duration, months 39.5  20.6
Baseline PFTsa
FVC, % predicted 60.9  17.5
TLC, % predicted 54.7  15.2
DLco, % predicted 30.9  14.9
Baseline ABG
PaO2, mm Hg 71.8  13.4
PaCO2, mm Hg 40.4  3.9
SaO2,% 94.3  3.3
Baseline 6MWTb
Distance, m 280.5  138.7
Initial SpO2, % 95.8  3.3
Lowest SpO2, % 85.6  7.8
Initial Borg score 0.4  0.8
Final Borg score 4  2.9
Treatment, n (%)
Corticosteroids 19 (67.9)
Immunomodulatorsc 16 (57.1)
Data are presented as means  standard deviations or number (with
See the legend to Table 1 for an explanation of the abbreviations tha
Abbreviations: IPF Z idiopathic pulmonary fibrosis; PFTs Z pulmona
cpapcity; TLC Z total lung capacity; DLCO Z diffusion capacity of
PaCO2Z partial pressure of carbon dioxide; SaO2Z oxygen saturation
oximetry.
a Three patients in the CTD-UIP group and two patients in the IPF/
patients in the LD-CTD group, five patients in the CTD-UIP group, and n
b Six patients in the CTD-UIP group and eight patients in the IPF/UI
c Including azathioprine, cyclophosphamide, cyclosporine, and mycpolymyositis/dermatomyositis (n Z 2). Comparisons of
demographic and clinical characteristics among patients
with LD-CTD, CTD-UIP, and IPF/UIP are shown in Table 2.
The LD-CTD and CTD-UIP patients were younger, more
often female, and far more likely to be nonsmokers than
those in the IPF/UIP group. The disease duration (the time
from the first respiratory symptoms until the last follow-up
in the ILD clinic) was significantly longer for LD-CTD and
CTD-UIP patients compared to IPF/UIP patients
(p Z 0.006). No patient in the LD-CTD group reported any
systemic symptom or sign suggestive of CTD either during
the first manifestation of the disease or during follow-up in
the ILD clinic. As expected, dyspnea was the most common
respiratory symptom; however, no significant difference
was noted across the three groups [LD-CTD, 93% of
patients; CTD-UIP, 100% of patients; and IPF/UIP, 97% of
patients; p Z 0.32]. In addition, no significant difference
was noted for dry cough, which was also quite common [LD-
CTD, 86% of patients; CTD-UIP, 90% of patients; and IPF/
UIP, 86% of patients; p Z 0.89]. Clubbing was less
commonly seen in patients with CTD-UIP compared to those
with LD-CTD and IPF/UIP [24%, 50%, and 57%, respectively;
p Z 0.01]. Baseline pulmonary function tests, arterial
blood gas values, and 6MWT results were all similar among
the three groups. More patients with LD-CTD and CTD-
UIP received corticosteroids and/or immunomodulatorscohort.
CTD-UIP n Z 29 IPF/UIP n Z 61 p-value
55.7  14.2 62.3  12.7 0.046
21 (72.4) 29 (47.5) 0.042
4 (14.3) 24 (40) 0.004
39.3  20.1 28.8  14.9 0.006
61.4  17.7 62.3  21.9 NS
63.8  19.9 60.0  17.8 NS
39.9  18.9 40.9  20.7 NS
73.1  12.5 68.7  11.7 NS
40.5  4.2 41.3  6.5 NS
95.1  3.4 94.0  3.8 NS
315.9  115.2 283.7  143.7 NS
96.5  1.9 95.0  3.3 NS
88.1  7.7 85.7  7.3 NS
0.3  0.9 1  1.6 0.051
3.5  2.5 4.7  3.2 NS
19 (65.5) 23 (37.7) 0.007
13 (44.8) 13 (21.3) 0.002
percentages).
t are not listed below.
ry function tests; ABG Z arterial blood gas; FVC Z forced vital
lung for carbon monoxide; PaO2 Z partial pressure of oxygen;
; 6MWTZ 6-min walk test; and SpO2Z oxygen saturation by pulse
UIP group could not perform pulmonary function tests, and two
ine patients in the IPF/UIP group could not perform the DLco test.
P group could not perform the 6MWT test.
ophenolate mofetil.
Table 3 Autoantibody profiles of the study cohort.
Serological
tests
LD-CTD
n Z 28
CTD-UIP
n Z 29
IPF/UIP
n Z 61
p-value
ANA 23 (82.1) 24 (83) 22 (36) <0.0001a
RF 5 (17.8) 16 (55) 4 (7) <0.0001a
Anti-CCP 2 (7.1) 3 (10) 0 (0) NSb
Anti-Scl70 2 (7.1) 2 (6.9) 0 (0) NSb
Anti-dsDNA 4 (14.3) 6 (21) 0 (0) NSb
Anti-Ro/SSA 5 (17.8) 7 (24) 0 (0) NSb
Anti-La/SSB 1 (3.6) 1 (3.4) 0 (0) NSb
Anti-RNP 2 (7.1) 6 (21) 0 (0) NSb
Anti-Smith 2 (7.1) 2 (6.9) 0 (0) NSb
Anti-JO-1 0 (0) 3 (10) 0 (0) NSb
Data are presented as number (%). Some patients had multiple
positive serological tests.
a Chi-square test (significant when LD-CTD and CTD-UIP were
compared to IPF/UIP).
b Fisher’s exact test (when LD-CTD was compared to
CTD-UIP).
Autoimmune usual interstitial pneumonia 1579(azathioprine, cyclophosphamide, cyclosporine, or myco-
phenolate mofetil) compared to those with IPF/UIP
(p Z 0.007 and p Z 0.002, respectively).
Laboratory findings
Themean serumalbumin concentrations obtainedwithin one
month of the initial evaluation showed no significant differ-
ence across the groups [LD-CTD, 33.8  4.8; CTD-UIP,
31.7  6.9; IPF/UIP, 31.0  5.4; p Z 0.1]. Comparisons of
the autoantibody profiles among the three groups (Table 3)Table 4 Radiographic and hemodynamic findings in the study c
Variable LD-CTD n Z 28 C
Typical UIP 22 (78.6) 2
Non etypical UIP 6 (21.4) 6
HRCT scores
Total extent 8.21  2.45 7
Ground glass opacity 1.39  0.78 1
Reticulation 1.82  0.61 1
Honeycombing 1.43  0.57 1
Traction bronchiectasis 1.96  0.99 1
Architectural distortion 0.96  0.57 0
Emphysema 0.14  0.35 0
Hemodynamic dataa
PH, present/absent 7/11 6
mPAP, mmHg 23.9  7.5 2
RAP, mmHg 5.4  3.3
sPAP, mmHg 38.1  10.1 3
PCWP, mmHg 11.2  6.3
PVR, wood units 3.0  2.1
CO, L/min 4.8  1.5
Data are presented as means  standard deviation or as number (wit
Abbreviations: HRCT Z high-resolution computed tomography; PH Z
sure; RAP Z right arterial pressure; sPAP Z systolic pulmonary a
PVR Z pulmonary vascular resistance; and CO Z cardiac output.
a Hemodoynamic data were obtained for patients with LD-CTD, n Zshowed that ANA was the most frequently positive autoanti-
body (n Z 23; 82.1%) in the LD-CTD group; 19 patients had
ANA titers  1280 (15 were women and five were men), one
had a titer of 320, one had a titer of 80, and two had titers of
40. Among the five patients with negative ANA titers, three
were positive for anti-CCP, one for anti-dsDNA, and one for
anti-SSA. Among the ANA-positive patients, the patterns of
immunofluorescence staining included speckled (9 patients),
homogeneous (7), nucleolar (5), speckled and homogeneous
(1), and speckled and nucleolar (1). Sixteen of the LD-CTD
patients (57.1%) were positive for one antibody, eight
(28.6%)werepositive for twoantibodies, and four (14.3%) had
three or more positive serological tests. Within the IPF/UIP
group, 22 patients (36%) had ANA titers 160 (16 speckled, 5
homogeneous, and 1 speckled and homogeneous). Only four
patients were positive for RF (titer  40). The centromeric
pattern was not observed in any of the groups.
Radiographic and pathological results
Comparisons of the chest HRCT findings and scores among
LD-CTD, CTD-UIP, and IPF/UIP patients are summarized in
Table 4. Evaluation of CT scores for the extent of paren-
chymal abnormalities revealed that the LD-CTD patients
had higher reticulation scores than the CTD-UIP or IPF/UIP
patients (p Z 0.044). The total extent and ground-glass
opacity scores were higher in the LD-CTD patients and the
traction bronchiectasis and architectural distortion scores
were higher among the IPF/UIP group, but these differ-
ences were not significant. Even though the majority of the
CTD-UIP patients where nonsmokers, the emphysema score
in this group was relatively high, similar to that in the IPF/
UIP group; however this difference was not significant.ohort.
TD-UIP n Z 29 IPF/UIP n Z 61 p-value
3 (79.3) 54 (88.5)
(20.7) 7 (11.5)
.41  2.58 8.0  3.06 NS
.17  0.71 1.23  0.80 NS
.52  0.63 1.57  0.69 0.044
.38  0.67 1.44  0.62 NS
.86  0.91 2.18  0.90 NS
.97  0.68 1.11  0.79 NS
.52  0.3 0.46  0.88 NS
/11 17/28 NS
4.3  6.7 24.3  7.4 NS
4.5  2.8 5.4  3.8 NS
6.3  11.3 38.1  10.1 NS
9.2  2.7 9.9  4.8 NS
4.1  3.4 3.2  1.8 NS
4.3  1.1 4.9  1.2 NS
h percentages).
pulmonary hypertension; mPAP Z mean pulmonary artery pres-
rtery pressure; PCWP Z pulmonary capillary wedge pressure;
18; CTD-UIP, n Z 17; and IPF/UIP, n Z 45.
Table 5 Histopathologic findings among patients with surgical lung biopsy.
Lymphoid
aggregates
Lymphoid
aggregates with
germinal enters
Plasmacytic
infiltration
Pleuritis Dense
perivascular
collagen
LD-CTD
Subject 1 e þ þ þ e
Subject 2 e þ þ þ e
Subject 3 þ e þ e e
Subject 4 þ e þ e e
CTD-UIP
Subject 1 e þ þ e e
IPF/UIP
Subjects 1e4 þ e e e e
Subjects 5e9 e e e e e
(þ) Z present; () Z absent.
Figure 1 KaplaneMeier survival curves for cases with lung-
dominant connective tissue disease (LD-CTD) (n Z 28, solid
line), CTD-associated usual interstitial pneumonia (UIP)
(n Z 29, dotted line), and idiopathic pulmonary fibrosis (IPF/
UIP) (n Z 61, dashed line).
1580 E.H. Alhamad et al.The typical UIP pattern was found in 22 LD-CTD patients
(78.6%), 23 CTD-UIP patients (79.3%), and 54 IPF/UIP patients
(88.5%). BasedonHRCT images, fourpatientswith nontypical
UIP in the LD-CTD group, one patient with nontypical UIP in
the CTD-UIP group, and two patients with typical UIP and
seven patients with nontypical UIP in the IPF/UIP group
underwent surgical lung biopsies. Their histopathological
findings were consistent with UIP. Among the LD-CTD
patients with histopathological features suggestive of CTD
(Table 5), two patients had lymphoid aggregates with
germinal center formation, prominent plasmacytic infiltra-
tion, andmild focal pleuritis. The other two patients showed
mild plasmacytic infiltration and lymphoid aggregates
without germinal center formation. In the CTD-UIP group,
a surgical lung biopsy was only available for one patient; this
individual showed lymphoid aggregates with germinal center
formation and prominent plasmacytic infiltration. In the IPF/
UIP group, mild lymphoid aggregates without germinal
centers were noted in four patients. No IPF/UIP patient
showed pleuritis or prominent plasmacytic infiltration.
Furthermore, dense perivascular collagen was not identified
in any of the LD-CTD, CTD-UIP or IPF/UIP patients.
Hemodynamic findings
The hemodynamic data, which were taken from available
right heart catheterization results, are summarized in Table
4. PH was detected in 38.8% of patients with LD-CTD, 35.3%
of patients with CTD-UIP, and 37.8% of patients with IPF/
UIP. These data were not significantly different among the
groups.
Survival analysis
During the study, there were 23 deaths [6 patients with LD-
CTD, 2 with CTD-UIP, and 15 with IPF/UIP) and five patients
were lost to follow-up [1 with LD-CTD, 2 with CTD-UIP, and
2 with IPF/UIP]. Respiratory causes accounted for 83.3% of
the deaths in the LD-CTD group (3 acute exacerbation, 2
secondary to respiratory failure), 100% in the CTD-UIP group
(1 respiratory failure, 1 acute exacerbation) and 66.6%
in the IPF/UIP group (4 respiratory failure, 4 acuteexacerbation, 1 lung cancer, and 1 pulmonary embolism).
The remaining causes of death were 1 cerebrovascular
accident in the LD-CTD group, and 5 sudden deaths in the
IPF/UIP group.
Patients with CTD-UIP had a better survival rate than
patients with IPF/UIP (p Z 0.028) (Fig. 1). However, there
was no significant difference in survival between patients
with LD-CTD and CTD-UIP (p Z 0.25) or between patients
with LD-CTD and IPF/UIP (p Z 0.16). The 3-year mortality
rates for LD-CTD, CTD-UIP, and IPF/UIP were 30%, 16.7%,
and 33.3%, respectively.
The results from our univariate analyses of risk factors
for mortality in patients with LD-CTD and IPF/UIP are shown
in Tables 6 and 7. In the LD-CTD group, the variables
associated with improved survival included corticosteroid
use, higher 6MWD (for each 1 m increase), less oxygen
Table 6 Predictors of survival in patients with LD-CTD,
identified using a univariate Cox model.
Variable HR 95% CI p-value
Age 1.02 0.95e1.09 NS
Female gender 0.50 0.07e3.57 NS
Ever smoker 2.3 2.40e22.21 NS
Corticosteroids 0.09 0.01e0.95 0.048
Immunomodulators 7.38 0.82e66.50 0.075
Physiological tests
FVC, % predicted 0.96 0.91e1.00 NS
TLC, % predicted 0.94 0.89e1.00 0.058
DLco, % predicted 0.95 0.83e1.10 NS
PaO2 mmHg 1.00 0.93e1.07 NS
6MWD, m 0.99 0.98e1.00 0.048
Initial SpO2, % 0.22 0.68e1.09 NS
Lowest SpO2, % 0.86 0.75e0.99 0.038
Lab and hemodynamic tests
Serum albumin, g/L 0.85 0.74e0.97 0.018
mPAP 25 mmHg 4.9 0.50e47.99 NS
HRCT scores
Total extent 1.11 0.77e10.60 NS
Ground glass opacity 2.51 0.93e6.76 0.068
Reticulation 1.19 0.20e7.09 NS
Honeycombing 1.56 0.37e6.52 NS
Traction bronchiectasis 1.14 0.49e2.60 NS
Architectural distortion 0.72 0.14e3.54 NS
Emphysema 0.02 0.00e113.69 NS
Abbreviations: HRZ hazard ratio; and 95% CIZ 95% confidence
interval.
See the legends to Tables 2 and 4 for an explanation of the other
abbreviations.
Table 7 Predictors of survival in patients with IPF/UIP,
identified using a univariate Cox model.
Variable HR 95% CI p-value
Age 0.99 0.96e1.03 NS
Female gender 0.52 0.18e1.46 NS
Ever smoker 1.24 0.44e3.50 NS
Corticosteroids 1.10 0.39e3.07 NS
Immunomodulators 1.19 0.40e3.51 NS
Physiological tests
FVC, % predicted 0.96 0.93e0.99 0.007
TLC, % predicted 0.96 0.93e0.99 0.023
DLCO, % predicted 0.98 0.94e1.02 NS
PaO2, mmHg 0.96 0.92e1.01 NS
6MWD, m 0.99 0.98e0.99 0.007
Initial SpO2, % 0.68 0.57e0.81 <0.0001
Lowest SpO2, % 0.92 0.85e0.99 0.040
Lab and hemodynamic tests
Serum albumin, g/L 0.79 0.71e0.88 <0.0001
mPAP 25 mmHg 0.85 0.21e3.40 NS
HRCT scores
Total extent 1.30 1.09e1.54 0.003
Ground glass opacity 1.20 0.62e2.32 NS
Reticulation 3.6 1.67e7.80 0.001
Honeycombing 2.41 1.12e5.19 0.024
Traction bronchiectasis 2.33 1.20e4.51 0.012
Architectural distortion 2.24 1.18e4.25 0.013
Emphysema 1.15 0.62e2.12 NS
Abbreviations: HRZ hazard ratio; and 95% CIZ 95% confidence
interval.
See the legends to Tables 2 and 4 for an explanation of the other
abbreviations.
Autoimmune usual interstitial pneumonia 1581desaturation during exercise (for each 1% increase), and
higher serum albumin (for each 1-g per liter increase). In
the same group, worsened survival with a trend for statis-
tical significance was noted for higher ground-glass opacity
scores [hazard ratio (HR), 2.51; 95% confidence interval
(CI), 0.93e6.76; p Z 0.068). There was no difference in
survival between LD-CTD patients with ANA titers 1280
versus those with ANA titers <1280 (data not shown).
In CTD-UIP patients, two factors were associated with an
increased risk of death: a higher honeycombing score (HR,
12.04; 95% CI, 1.14e126.83; p Z 0.038) and a higher
emphysema score (HR, 3.66; 95% CI, 1.23e11.96;
p Z 0.031). However, some physiological variables could
not be determined in this group because the two patients
who died were too ill to perform all tests prior to their
deaths. In addition, because of the small sample sizes and
low number of deaths, multivariate analyses were not
performed for the LD-CTD and CTD-UIP groups.
Six variables were associated with improved survival for
patients with IPF/UIP: higher FVC (for each 1% increase);
higher TLC (for each 1% increase); increasing walking
distance (for each 1 m increase); higher initial SpO2 (for
each 1% increase); less oxygen desaturation during exercise
(for each 1% increase); and higher serum albumin (for each
1 g increase). In contrast, the variables associated with
significant increases in the risk of mortality for this group
were related to HRCT score; these included total extent,reticulation, honeycombing, traction bronchiectasis, and
architectural distortion.
Multivariate analyses identified three independent
predictors of mortality in IPF/UIP patients: lower resting
SpO2 level (HR, 2.08 for each 1% decrease; 95% CI, 1.6e2.6;
pZ 0.004); higher total parenchymal score (HR, 4.0; 95% CI
1.2e13.5; p Z 0.026); and lower serum albumin (HR 1.34
for each 1-g per liter decrease; 95% CI, 1.1e1.6;
p Z 0.026).
Multivariate analysis of all UIP patients showed that
a lower resting SpO2 level (HR, 2.89 for each 1% decrease;
95% CI 2.1e3.7; p Z 0.009) and lower serum albumin (HR
2.16 for each 1-g per liter decrease; 95% CI 1.6e2.7;
pZ 0.008) were associated with an increased risk of death.Discussion
The present study demonstrates that approximately one
fourth of patients with UIP have clinical and laboratory
features suggestive of an autoimmune background but do
not fulfill the classification criteria for well-defined CTD.
It is not uncommon for an autoimmune disease to target
the lungs in the absence of extrathoracic features of CTD; it
has been estimated that up to 20% of cases of chronic ILD
are either due to occult CTD or subsequently evolve into
definite CTD.30,31 The term UCTD was proposed to describe
1582 E.H. Alhamad et al.patients that do not meet the ACR criteria for any of the
CTDs. Estimates suggest that 70% of these undifferentiated
cases will remain unclassifiable, showing only mild signs of
autoimmune disease without major organ involvement.11
Recently, a few studies have specifically addressed lung
involvement, particularly idiopathic nonspecific interstitial
pneumonia (NSIP), among patients fulfilling the diagnostic
criteria for UCTD.32e35 However, the diagnostic criteria for
UCTD include the symptoms of gastroesophageal reflux and
arthralgia, which are nonspecific and commonly encoun-
tered in patients with many forms of ILD in the absence of
definite CTD.
In the present study, we used the term LD-CTD proposed
by Fischer et al.12 to describe patients with UIP patterns
that have autoimmune features but insufficient extra-
thoracic features for a definite diagnosis of CTD. We did not
use the term UCTD, because our patients lacked the
specific symptoms and signs of autoimmune disease
included in the criteria for UCTD.
During the initial evaluation, dyspnea and dry cough
were the most common complaints among the LD-CTD
patients. None of these patients reported systemic symp-
toms or signs of autoimmune disease either at presentation
or during follow up, even though their mean disease dura-
tion exceeded 3 years. This lack of systemic symptoms may
indicate that the LD-CTD group represents a distinct clinical
entity, or it could be related to treatment effects. Nearly
two thirds of these patients were treated with corticoste-
roids and more than half received immunomodulatory
treatments, which may have masked their systemic symp-
toms or prevented the overt development of defined CTD.
Interestingly, adopting the proposed criteria for LD-CTD
yielded a group of patients with characteristics similar to
those of CTD-UIP patients (younger age, more often
female, predominantly nonsmokers, and positive ANA titer)
but distinct from those of the IPF/UIP group. Our findings
are consistent with other reports of idiopathic NSIP patients
that met the diagnostic criteria for UCTD,32e35 but differ
from those reported in a recent study of patients with
autoimmune featured-ILD [predominantly male (60%) and
older (average 66 years old)].36 The reason for these
discrepancies is unknown. Racial differences may be rele-
vant, as patients studied by Vij et al.36 were white, black,
and Hispanic, whereas our patients were Arabs. In the
future, it will be useful to study patients who meet the
diagnostic criteria for LD-CTD among different populations.
HRCT findings typical of UIP tend to highly correspond
with the pathological patterns of UIP. Indeed, recently
published international guidelines indicate that IPF can be
accurately diagnosed by HRCT in the absence of a surgical
lung biopsy when a radiographic UIP pattern is present.5 A
previous study showed that CTD-UIP patients were more
likely to show nontypical UIP patterns compared to those
with IPF.4 However, the majority of patients in our study
had a typical UIP pattern regardless of UIP type. This may
reflect methodological differences; we implemented
a multidisciplinary approach involving pulmonologists,
radiologists and pathologists when surgical biopsy was
performed on all ILD patients, thereby improving the
accuracy of UIP diagnosis. Furthermore, the NSIP pattern is
commonly observed in patients with CTDs, but the diag-
nostic accuracy of NSIP based on HRCT is notoriouslyinaccurate.37,38 Here, we excluded NSIP cases lacking
surgical lung biopsies, potentially accounting for the lower
number of nontypical cases in our cohorts.
The criteria for LD-CTD proposed by Fischer at al.12
included histopathological features that should raise the
suspicion of an underlying occult CTD. Song et al.4 noted
higher germinal center scores and more plasma cells among
IPF/UIP patients with positive autoantibodies (ANA or RF)
compared to IPF/UIP patients with negative autoanti-
bodies. Interestingly, none of the pathological variables
described in the cited study could be used to distinguish
between IPF/UIP with positive autoantibodies and CTD-UIP,
suggesting that the two groups share common mechanisms
leading to pathological similarities.4 Although we enrolled
too few cases with available surgical lung biopsies to draw
a firm conclusion, our findings showed that the IPF/UIP
group did not have these histopathological features when
compared to the LD-CTD and CTD-UIP groups. This supports
the notion that the proposed histological features may be
useful for identifying a subset of patients with an occult
CTD, particularly in the presence of circulating autoanti-
bodies. Future large studies are needed to explore whether
the type or cutoff levels of circulating autoantibodies can
correlate with or predict certain histopathological features
in LD-CTD.
Pulmonary hypertension (PH) is a well-known complica-
tion in many forms of ILD. In CTD, PH may occur in asso-
ciation with ILD or in isolation as a result of direct vascular
involvement (pulmonary arterial hypertension). Among
patients with available right heart catheterization data,
the prevalence of PH was remarkably similar across the
three groups regardless of the UIP type. In addition, there
was no significant difference in hemodynamic data across
the three groups. Our data therefore suggest that the three
forms of UIP studied herein may share common mechanisms
in the genesis of PH.
The prognostic value of patients fulfilling the diagnostic
criteria for UCTD in IIP was recently examined. Vij et al.36
reported that autoimmune-featured ILD was associated
with a poor survival similar to that of IPF patients. In
another study, Corte et al.35 noted that UCTD was present
in 21% of their IIP cohort, and showed no survival benefit
compared to patients without UCTD. Our findings agree
with those of Vij et al.36 and Corte et al.35 in that no
significant survival difference was noted between patients
with LD-CTD and IPF/UIP. However, when a patient lacks
a surgical lung biopsy and the HRCT is not typical of UIP,
a diagnosis of UCTD may have prognostic implications.
Corte et al.35 reported that among IIP patients who lacked
histological information and had HRCTs atypical of UIP,
a diagnosis of UCTD was associated with lower mortality
independent of the severity of the underlying fibrosis (HR
0.38, 95% CI 0.16e0.91; p Z 0.03).
Limited studies have examined the prognostic signifi-
cance of ANA titers in patients with IIP. Corte et al.35 found
no association between positive autoimmune serology and
survival in IIP patients with UCTD. Song et al.4 reported no
significant difference in survival between patients having
IPF with positive antibodies compared to those with nega-
tive antibodies. However, neither of these prior studies
reported ANA titer cutoffs. In the present study, we found
no survival benefit among patients having LD-CTD with high
Autoimmune usual interstitial pneumonia 1583ANA titers. The results of our study contradict the findings
of Vij et al.,36 where improved survival was noted among
patients with autoimmune-featured ILD with ANA titers
1280 versus <1280. Differences in the demographic and
clinical characteristics of the patients in the cited study36
and ours may explain the observed variations. The
majority of high-ANA-titer patients in the present study
were women (79%), whereas only 53% of these patients
were women in the prior study.36 Furthermore, we
excluded patients with unclassifiable fibrosis or patients
with NSIP patterns based on HRCT in the absence of path-
ological information. As such, our LD-CTD cohorts were
homogeneous and included only UIP patterns. In contrast,
Vij et al.36 acknowledged that their autoimmune featured-
ILD with high ANA titer groups were heterogeneous,
including typical and atypical UIP patterns observed on
HRCT, as well as patients with NSIP and those considered
“unclassifiable” based on pathological findings. Future
prospective studies are needed to examine the true impact
of positive autoantibodies in IIP patients with regard to
treatment response, disease progression and survival.
A striking finding of our study was the prognostic
importance of the serum albumin concentration, as our
univariate analysis showed that lower levels were associ-
ated with an increased risk of death among patients with
LD-CTD and IPF/UIP. This is particularly interest given that
albumin concentration was one of only two independent
predictors of mortality identified in our multivariate anal-
ysis of all UIP patients (regardless of UIP type). These
findings agree with those of Zisman and colleagues,39 who
identified low serum albumin as an independent predictor
of mortality in patients with idiopathic interstitial pneu-
monia listed for lung transplantation.
Hypoalbuminemia, a marker of malnutrition and under-
lying inflammation, has been shown to be an important
predictor of mortality in patients various diseases.40e42
Albumin has many important physiological functions,
including its ability to act as an antioxidant. Thus,
a decrease in serum albumin could decrease the antioxi-
dant capacity and increase the noxious effects of oxidative
stress. Several studies have suggested that oxidant/anti-
oxidant imbalances play an important role in the patho-
genesis of pulmonary fibrosis.43e46 One of the key
mechanisms by which serum albumin protects tissues
against oxidative injury is via the regulation of glutathione
levels. In human cell culture experiments, Cantin and
colleagues47 demonstrated that adding human serum
albumin: 1) increased cellular glutathione levels, which can
protect lung epithelial cells against hydrogen peroxide-
mediated cytotoxicity; and 2) decreased the activation of
oxidant-sensitive transcription protein complex nuclear
factor-kappa B by tumor necrosis factor-a, which is known
to perpetuate inflammatory reactions in the lower respi-
ratory tract. Another mechanism that has been implicated
in the pathogenesis of pulmonary fibrosis is apoptosis; an
increase in apoptosis has been identified as immediately
underlying the accumulation of myofibroblasts in fibro-
blastic foci, suggesting that this may be an important
mechanism in triggering epithelial cell death, preventing
epithelial repair, and promoting fibrosis.48 Interestingly,
albumin has been shown to play an important role in pre-
venting apoptosis among human endothelial cells.49 We donot propose that administering albumin to patients with
hypoalbuminemia will improve survival, as this treatment
has not been shown to alter the outcome when given to
critically ill patients.50 However, our findings suggest that
low albumin status may be a marker for increased disease
activity leading to decreased survival, as observed in our
UIP patients.
The present study had several limitations. First, surgical
lung biopsies were performed on only a few patients in
whom we could not validate the histopathological features
suggested by Fischer and colleagues12 as provisional criteria
for LD-CTD. Nevertheless, when we applied the proposed
criteria for LD-CTD without relying on the suggested histo-
pathological features of CTD, we obtained a group of
patients with demographic characteristics distinct from
those of patients with IPF/UIP. However, the majority of
the patients in the LD-CTD group received corticosteroids
and/or immunomodulators, potentially accounting for the
absence CTD symptoms and possibly preventing the devel-
opment of overt CTD during the follow-up period.
Furthermore, the prognostic implications of treating
patients with LD-CTD should be interpreted with caution
because our sample size was rather small and the patients
received non-identical treatments. UIP cases may have
been missed among patients with HRCT-based diagnoses of
NSIP when surgical lung biopsy was not performed, perhaps
introducing a selection bias. Finally, independent predic-
tors of mortality could not be determined for the LD-CTD
and CTD-UIP groups, due to the small sample size and low
number of deaths.
In conclusion, we herein show that LD-CTD has distinct
clinical and serological characteristics suggestive of an
autoimmune background that resembles CTD-UIP but
differs from IPF/UIP. However, LD-CTD with a UIP pattern
was not associated with improved survival. Resting oxygen
saturation and serum albumin were independent predictors
of mortality in all UIP patients.
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